Changes in the epigenetic status of miR-155HG promoter have been reported to contribute to the transcriptional control of miR-155 expression levels in B-lymphocytic leukemia (B-CLL) and breast cancer.49, 50, 51 We therefore evaluated whether epigenetic modifications occurred on the surrounding miR-155HG and antisense lncRNA-155HG genomic regions following Ago2-depletion by analyzing their chromatin acetylation status. Here, AGO2 is linked to breast carcinoma.